Oncotype DX Genomic Prostate Score

How Does It Compare to Other Tests?

The Oncotype DX GPS is the only genomic test that was designed specifically for use in men with clinically low risk cancer (GS 3+3 or 3+4) who are deciding between active surveillance or treatment. The test:

THE ONLY GENOMIC ASSAY DESIGNED TO HELP MAKE TREATMENT DECISIONS AT THE TIME OF DIAGNOSIS
  • Provides unique biologic information on individualized risk to help management of treatment choices for your clinically low-risk prostate cancer patients.
  • Uses a small sample from your patient’s tumor biopsy and provides an easy-to-understand score that gives an indication of the patient's likelihood of favorable pathology.
  • Provides actionable information that can inform individualized management planning for your patients, based on the likelihood of favorable pathology.

Not all genomic tests are the same

Select a test feature to see how the Oncotype DX GPS test compares to other genomic tests.

Type of Test Result

Genomic Health
Genomic Prostate Score:
Predicts the likelihood of Prostate Cancer Death and Metastasis within 10 years after RP, and Adverse Pathology* using multiple genomic pathways
Prolaris®
Myriad Genetics
Cell Cycle Progression Score:
Reports the risk of dying from untreated disease in ten years, using a single genomic pathway
Decipher®
GenomeDx Bioscience
Genomic Classifier:
Predicts the probability of metastasis after surgery or radiation using multiple genomic pathways
Promark®†
Metamark Genetics
ProMark Score:
Predicts likelihood of Adverse Pathology using protein staining
ConfirmMDx®
MDx Health
ConfirmMDx result:
Predicts likelihood of negative repeat biopsy
4KScore®
Opko
4KScore:
Provides probability of aggressive cancer on initial biopsy
Validated endpoint(s) in a biopsy setting

Genomic Health
  • Adverse Pathology
  • Biochemical Recurrence, Prostate Cancer Death and Metastasis within 10 years after RP
  • High Grade Disease
  • Non-Organ Confined Disease
Prolaris®
Myriad Genetics
  • 10-year Untreated Mortality
  • Biochemical Recurrence
  • Metastasis after RP
Decipher®
GenomeDx Bioscience
  • High Grade Disease
  • 10-year Metastasis after RP
  • Metastasis after radiation therapy
Promark®†
Metamark Genetics
  • Adverse Pathology
  • High Grade Disease
  • Non-Organ Confined Disease
ConfirmMDx®
MDx Health
Negative Repeat Biopsy
4KScore®
Opko
Likelihood of GS 3+4 and higher at initial biopsy
Biomarker selection specific for prostate cancer

Genomic Health
YES
Prolaris®
Myriad Genetics
NO
Decipher®
GenomeDx Bioscience
YES
Promark®†
Metamark Genetics
YES
ConfirmMDx®
MDx Health
YES
4KScore®
Opko
YES
Patient Specimen

Genomic Health
Positive Biopsy
NCCN® Very Low, Low, Favorable-Intermediate risk GS 3+3, 3+4
Prolaris®
Myriad Genetics
Positive Biopsy
AUA® Low-High Risk
Decipher®
GenomeDx Bioscience
Positive Biopsy
NCCN Low-High Risk
Promark®†
Metamark Genetics
Positive Biopsy
GS 3+3, 3+4
ConfirmMDx®
MDx Health
Negative Biopsy
HGPIN Biopsy
4KScore®
Opko
Blood
Biopsy eligible patients
Patient Access

Genomic Health
Medicare Reimbursed for biopsy NCCN Very Low/Low and Favorable Intermediate
Financial Assistance Available
Prolaris®
Myriad Genetics
Medicare Reimbursed for biopsy NCCN Very Low/Low and Favorable Intermediate
Financial Assistance Available
Decipher®
GenomeDx Bioscience
Medicare Reimbursed in Post RP Only
Financial Assistance Available
Promark®†
Metamark Genetics
Medicare Reimbursed for biopsy NCCN Very Low/Low
Financial Assistance Available
ConfirmMDx®
MDx Health
Medicare Reimbursed
Financial Assistance Available
4KScore®
Opko
Financial Assistance is not reported on website

Download Comparison Chart (PDF)



Genomic testing vs. genetic testing

Genetic tests typically screen for inherited risk factors and identify changes in chromosomes and genes—which can help in understanding patient risk for having cancer or other diseases.

Genomic tests examines the expression of genes within a sample of tumor tissue to provide unique information about tumor biology that other clinical pathological factors simply cannot. The activity and interaction of genes influences the aggressiveness of a tumor, including how likely it is to grow and spread.

FOOTNOTES

*Adverse Pathology is defined as high-grade and/or non-organ-confined disease.

†ProMark relies on proteomic testing.

National Comprehensive Cancer Network, NCCN, and NCCN Guidelines are registered trademarks of the National Comprehensive Cancer Network. NCCN does not endorse any therapy or product. AUA is a registered trademark of American Urological Association, AUA does not endorse any therapy or product.

Comparison Chart

Shows in a single glance how the Oncotype DX Genomic Prostate Score compares to other genomic tests.

Download

Get Our Patient Brochure

Download

Available Now

The Oncotype DX Genomic Prostate Score test predicts
both clinical risk and tumor aggressiveness.

Learn More

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™